Pluristem Soars Most in Four Months on Results of Cell Study

Pluristem Therapeutics Inc. surged the most in more than four months after the developer of cell-therapy products said a clinical trial of its PLX-PAD cells to treat critical limb ischemia met all the protocol endpoints.

The shares jumped 11 percent the most since June 20, to 9.92 shekels at 11:41 a.m. in Tel Aviv, giving the Haifa, Israel-based company a market value of 426 million shekels ($116 million).

Before it's here, it's on the Bloomberg Terminal. LEARN MORE